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Abstract
Background The addition of mTOR inhibitor everolimus
(EVE) to exemestane (EXE) was evaluated in an interna-
tional, phase 3 study (BOLERO-2) in patients with hor-
mone-receptor-positive (HR?) breast cancer refractory to
letrozole or anastrozole. The safety and efficacy of anti-
cancer treatments may be influenced by ethnicity (Sekine
et al. in Br J Cancer 99:1757–62, 2008). Safety and efficacy
results from Asian versus non-Asian patients in BOLERO-
2 are reported.
Methods Patients were randomized (2:1) to 10 mg/day
EVE ? EXE or placebo (PBO) ? EXE. Primary endpoint
was progression-free survival (PFS). Secondary endpoints
included overall survival, response rate, clinical benefit
rate, and safety.
Results Of 143 Asian patients, 98 received EVE ? EXE
and 45 received PBO ? EXE. Treatment with
EVE ? EXE significantly improved median PFS versus
PBO ? EXE among Asian patients by 38 % (HR = 0.62;
95 % CI, 0.41–0.94). Median PFS was also improved
among non-Asian patients by 59 % (HR = 0.41; 95 % CI,
0.33–0.50). Median PFS duration among EVE-treated
Asian patients was 8.48 versus 4.14 months for
PBO ? EXE, and 7.33 versus 2.83 months, respectively,
in non-Asian patients. The most common grade 3/4 adverse
Please note that although partial results were presented at the 2012
ASCO Annual Meeting, this article is an original work that has not
been published elsewhere, and all authors agree to its submission.
S. Noguchi (&)  T. Nakayama
Department of Breast and Endocrine Surgery,
Osaka University, Osaka, Japan
e-mail: noguchi@onsurg.med.osaka-u.ac.jp
N. Masuda
Department of Surgery, Breast Oncology, National Hospital
Organization, Osaka National Hospital, Osaka, Japan
H. Iwata
Department of Breast Oncology, Aichi Cancer Center Hospital,
Nagoya, Japan
H. Mukai
Department of Breast Oncology, National Cancer Center
Hospital East, Kashiwa, Japan
J. Horiguchi
Breast and Endocrine Surgery, Gunma University Hospital,
Maebashi, Japan
P. Puttawibul
Songklanagarind Hospital, Faculty of Medicine,
Prince of Songkla University, Songkhla, Thailand
V. Srimuninnimit
Siriraj Hospital, Mahidol University, Bangkok, Thailand
Y. Tokuda
Department of Breast and Endocrine Surgery,
Tokai University Hospital, Isehara, Japan
K. Kuroi
Department of Surgery, Tokyo Metropolitan Cancer
and Infectious Diseases Center Komagome Hospital,
Tokyo, Japan
H. Iwase
Department of Breast and Endocrine Surgery,
Kumamoto University, Kumamoto, Japan
H. Inaji
Department of Breast and Endocrine Surgery,
Osaka Medical Center for Cancer and Cardiovascular Diseases,
Osaka, Japan
123
Breast Cancer (2014) 21:703–714
DOI 10.1007/s12282-013-0444-8
events (stomatitis, anemia, elevated liver enzymes, hyper-
glycemia, and dyspnea) occurred at similar frequencies in
Asian and non-Asian patients. Grade 1/2 interstitial lung
disease occurred more frequently in Asian patients. Quality
of life was similar between treatment arms in Asian
patients.
Conclusion Adding EVE to EXE provided substantial
clinical benefit in both Asian and non-Asian patients with
similar safety profiles. This combination represents an
improvement in the management of postmenopausal
women with HR?/HER2- advanced breast cancer pro-
gressing on nonsteroidal aromatase inhibitors, regardless of
ethnicity.
Keywords Advanced breast cancer  Endocrine
resistance  Everolimus  Exemestane  Progression-free
survival
Introduction
Worldwide, breast cancer is the most common malignancy
in women and one of the leading causes of cancer deaths
[1–3]. Incidence of breast cancer in Asia is increasing [3].
In Asia, as in Western countries, treatment approaches for
breast cancer typically follow National Comprehensive
Cancer Network [4] and St. Gallen guidelines. For post-
menopausal patients with hormone-receptor-positive
(HR?) advanced breast cancer, aromatase inhibitors (ste-
roidal or nonsteroidal) are the standard initial treatment [4].
Even so, most patients are unresponsive to initial treatment
or acquire resistance. Other treatment options include
estrogen receptor (ER) antagonists (e.g., tamoxifen) and
ER downregulators (e.g., fulvestrant). These treatment
options provide limited clinical benefit once endocrine
resistance develops (especially after aromatase inhibitor
therapy), and survival is poor [5]. New treatment options
that can offer patients with advanced breast cancer the hope
of overcoming resistance and that can prolong the time of
effectiveness of endocrine therapy and delay chemotherapy
are needed.
Hyperactivation of the mammalian target of rapamycin
(mTOR) pathway is associated with breast cancer pro-
gression and with the development of endocrine resistance
[6]. Aberrations in phosphatidylinositol 3-kinase (PI3K)/
mTOR pathway protein expression are also associated with
poor prognosis in HR? breast cancer [7]. However, in vitro
and in vivo data indicate that mTOR inhibitors can inhibit
cell proliferation and restore sensitivity to fulvestrant,
letrozole, and tamoxifen [8–11].
Everolimus (Afinitor, Novartis) is an orally active mTOR
inhibitor. It is approved for the treatment of patients with pro-
gressive neuroendocrine tumors of pancreatic origin, advanced
renal cell carcinoma, and subependymal giant cell astrocytoma
associated with tuberous sclerosis [12]. Recently, everolimus
(EVE) was also approved in combination with exemestane
(EXE) for use in the USA and the 27 European Union member
states, plus Iceland and Norway, and in Mexico, Argentina, and
other Latin American countries, for the treatment of post-
menopausal patients with HR? breast cancer whose disease has
progressed during or after nonsteroidal aromatase inhibitor
therapy. This approval was based on outcomes from BOLERO-
2. In this phase 3 study, EVE ? EXE improved progression-
free survival (PFS) compared with EXE ? placebo (PBO;
median PFS = 7.8 months vs 3.2 months, respectively; hazard
ratio [HR] = 0.45; P\ 0.0001) [12].
Variations in the pharmacodynamics and pharmacoki-
netics of anticancer agents can be attributed in part to ethnic
differences, potentially resulting in alterations of their
safety and efficacy profiles [13]. In fact, some studies of
targeted therapies have shown that variability in safety and
efficacy is associated with patient ethnicity [14]. To ensure
an optimal treatment response is balanced with a manage-
able safety profile, the potential inter-ethnic differences
in anticancer drug effects should be considered [13].
Treatment for lung cancer using the epidermal growth
factor inhibitor gefitinib, for example, is more effective
in Asian patients than in patients of other ethnicities [15].
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The incidence of interstitial lung disease (ILD) is also more
prevalent in Asian patients treated with gefitinib mono-
therapy than in those of other ethnicities [15]. ILD is one of
the relatively common, serious adverse events (AEs) asso-
ciated with molecular targeted anticancer therapies, and
treatment with EVE has been associated with ILD [16, 17].
Thus, it is important to compare the frequency of AEs,
including ILD, induced by EVE in both Asian and non-
Asian patients.
To determine whether patient ethnicity has an effect on
the efficacy and safety of EVE ? EXE, we performed an
analysis in Asian versus non-Asian patients with HR?
advanced breast cancer in BOLERO-2 after a median fol-
low-up of 18 months.
Patients and methods
The BOLERO-2 study is an international, phase 3, multi-
center, randomized, double-blind, placebo-controlled trial
(ClinicalTrials.gov identifier NCT00863655). The protocol
and results for the entire study have been reported [16, 18].
Post hoc analyses of the data from Asian patients (who
selected Asian as their race at randomization) and non-
Asian patients included in BOLERO-2 are reported herein.
Patients
Patients were postmenopausal women with metastatic or
locally advanced, estrogen receptor-positive (ER?) human
epidermal growth factor receptor-2 nonamplified (HER2-)
breast cancer that had recurred or progressed during or after
letrozole or anastrozole therapy as described previously
[16]. This study was conducted in accordance with the
Declaration of Helsinki, in agreement with the institutional
review board at each participating center, in accordance
with Good Clinical Practice and applicable local regula-
tions. Every patient provided written informed consent.
Study design
Patients were randomized (2:1) to EVE (10 mg/day) ?
EXE (25 mg/day) or PBO ? EXE (25 mg/day). Random-
ization was stratified according to sensitivity to endocrine
therapy and the presence of visceral metastasis. Treatment
continued until disease progression, intolerable toxicity, or
withdrawal of consent. During the study, dose reductions or
interruptions were allowed to manage AEs. Crossover from
the PBO arm to the EVE arm was not allowed.
Study endpoints
The primary endpoint was PFS, defined as the time from
randomization to the first documentation of disease
progression (as assessed by the local investigator according
to Response Evaluation Criteria in Solid Tumors [RECIST]
[19] or, in the case of nonmeasurable disease, unequivocal
progression or appearance of new lesions) or death from
any cause. The key secondary endpoint was overall sur-
vival. Other secondary endpoints included overall response
rate (ORR), clinical benefit rate (CBR), and time to overall
response and duration of overall response according to
RECIST [19].
Efficacy and safety assessments
An independent data monitoring committee (IDMC) was
responsible for monitoring safety and pharmacokinetic data
as well as reviewing efficacy results at the interim and final
analyses. Tumor evaluation based on computed tomogra-
phy or magnetic resonance imaging was performed at
baseline (within 6 weeks before randomization) and every
6 weeks thereafter until disease progression and initiation
of further anticancer therapy. Objective tumor response and
disease progression were assessed per RECIST version 1.0
[19]. AEs were assessed at each study visit and were gra-
ded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0 [20].
Patient-reported outcomes
Quality of life (QOL) was evaluated using the European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30;
Version 3.0, 2001), a reliable and valid questionnaire
developed to assess the quality of life of cancer patients
[21, 22]. This self-administered questionnaire is composed
of 30 items arranged into a number of functional and
symptom subscales as well as a global health status (GHS)/
global QOL subscale, which was the primary QOL variable
of interest for BOLERO-2.
Statistical analyses
Progression-free survival was based on the intent-to-treat
analysis, according to the randomized treatment group and
stratification. Distribution of PFS was estimated using the
Kaplan–Meier method, and the HRs and corresponding
95 % confidence intervals (CIs) were estimated using the
Cox proportional hazard model. In addition, the protocol-
specified time to definitive deterioration (TTD) in the
EORTC QLQ-C30 GHS score (defined as a 5 % decrease
in QOL relative to baseline, with no subsequent increase
above this threshold) was calculated in the Asian subset
using Kaplan–Meier estimates and was described using
medians and 95 % CIs. The TTD was compared between
EVE ? EXE and PBO ? EXE using a log-rank test.
Breast Cancer (2014) 21:703–714 705
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Results
Patient characteristics
Median follow-up was 18 months at the time of this
analysis (cutoff date 15 December 2011). Of the 724
patients in BOLERO-2, 143 were Asian, with 106 (74.1 %)
of Japanese origin. There were 98 Asian patients in the
EVE ? EXE arm and 45 in the PBO ? EXE arm (Fig. 1).
Patient and disease characteristics at baseline among the
Asian and non-Asian patients were generally comparable,
although the Asian patients were younger and a greater pro-
portion had good performance status (Table 1). Among the
Asian population, there were more patients in the
EVE ? EXE arm who had at least 3 sites of metastases
compared with the PBO ? EXE arm. In the PBO ? EXE
arm, Asian patients had less visceral disease than non-Asian
patients. Prior treatments at study entry were mostly similar
between Asian and non-Asian patients. However, more non-
Asian patients in the EVE ? EXE arm received chemother-
apy in the metastatic setting than Asian patients (Table 1).
The median durations of exposure to treatment were
longer in Asian patients than in non-Asian patients. Among
Asian patients, median exposure to EVE was 27.6 weeks,
whereas median exposure to EXE was 32.6 weeks in the
EVE ? EXE arm and 18.0 weeks in the PBO ? EXE arm.
Among non-Asian patients, median exposure to EVE was
23.7 weeks; median exposure to EXE was 28.1 weeks in
the EVE ? EXE arm and 13.9 weeks in the PBO ? EXE
arm (Table 2).
Fig. 1 CONSORT flowchart. ITT intention-to-treat. Ongoing treatment refers to those patients at time of cutoff for this analysis. Note that
disease progression events in this figure are those that resulted in treatment discontinuation
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Table 1 Demographics of Asian versus Non-Asian population
Baseline demographics Asian Non-Asian
Everolimus ? exemestane
(n = 98)
Placebo ? exemestane
(n = 45)
Everolimus ? exemestane
(n = 387)
Placebo ? exemestane
(n = 194)
Age, years
Mean (SD) 59.9 (7.2) 58.6 (8.2) 63.1 (10.9) 61.8 (10.0)
Median (range) 59.5 (40.0–79.0) 60.0 (28.0–72.0) 63.0 (34.0–93.0) 61.0 (38.0–90.0)
Age group, %
\65 years 77.6 82.2 55.3 62.9
C65 years 22.4 17.8 44.7 37.1
Ethnicity, %
Chinese 5.1 0 0 0
Japanese 72.4 77.8 0 0
Mixed 1.0 0 2.1 3.1
Hispanic/Latino 0 0 7.2 5.2
Indian (subcontinent) 0 0 0.3 0
Other 21.4 22.2 90.4 91.8
Number of metastatic sites, %a
1 33.7 33.3 31.5 25.3
2 22.4 33.3 32.6 35.6
C3 42.8 33.3 35.7 39.2
ECOG performance status, %
0 82.7 86.7 54.8 53.1
1 15.3 13.3 41.1 40.2
2 0 0 2.3 3.6
Time between initial diagnosis and 1st recurrence/metastasis, %
\3 months 13.3 11.1 22.2 20.1
3 to \6 months 0 0 1.3 2.6
C6 months 80.6 80.0 69.3 71.6
Missing 6.1 8.9 7.2 5.7
Metastatic cancer sites, %
CNSb 2.0 0 1.0 0
Visceral (excluding CNS)c 59.2 53.3 58.1 60.8
Lung 34.7 31.1 28.2 33.5
Liver 31.6 22.2 33.9 32.5
Lung and liver 9.2 4.4 9.0 12.4
Bone 69.4 51.1 78.3 83.5
Bone only 20.4 11.1 22.0 21.1
Other 56.1 73.3 49.1 53.6
Previous chemotherapy, %
Adjuvant/neoadjuvant only 60.2 48.9 39.5 37.6
Metastatic only 6.1 11.1 15.8 9.3
Both 10.2 15.6 12.4 16.0
Number of previous chemotherapy lines in advanced setting, %
1 16.3 26.7 28.2 23.7
2 0 0 0 0
Data from 15 December 2011 safety update cutpoint
CNS central nervous system, ECOG Eastern Cooperative Oncology Group, SD standard deviation
a One patient each in the Asian and non-Asian subgroups had missing information
b CNS includes spinal cord, brain and meninges
c Visceral includes lung, liver, pleural, pleural effusions, peritoneum, and ascites
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The percentages of patients who required EVE dose
reductions or interruptions were similar between the Asian
and non-Asian patients (71.4 vs. 65.6 %), as were the
percentages of Asian and non-Asian patients who required
EXE dose reductions or interruptions while receiving
EVE ? EXE (22.4 vs. 24.2 %), respectively. In contrast,
Asian patients receiving PBO ? EXE required more EXE
dose reductions or interruptions than non-Asian patients
(26.7 vs. 8.3 %), respectively. Most of these dose reduc-
tions or interruptions were the result of an AE (data not
shown). At the time of cutoff, 15.4 % of Asian patients and
11.9 % of non-Asian patients were ongoing with study
treatment (Fig. 1). Among Asian patients, 82.7 % discon-
tinued EVE ? EXE treatment and 88.9 % discontinued
PBO ? EXE treatment, whereas 83.5 and 97.4 % of non-
Asian patients discontinued EVE ? EXE and PBO ? EXE
treatment, respectively (Fig. 1). Most of the patients who
discontinued treatment did so because of disease
progression.
Efficacy
The combination of EVE and EXE reduced the risk of
disease progression by 38 % among Asian patients com-
pared with PBO ? EXE (HR = 0.62; 95 % CI, 0.41–0.94;
Fig. 2). At the cutoff date, 17.3 % of Asian patients in the
EVE ? EXE arm and 11.1 % of patients in the PBO ?
EXE arm were progression free and remained on treatment,
whereas 71.4 % of Asian patients in the EVE ? EXE arm
and 84.4 % of patients in the PBO ? EXE arm had disease
progression (Fig. 1). Median PFS per local investigator
assessment among Asian patients in BOLERO-2 was
8.48 months for EVE ? EXE versus 4.14 months for
PBO ? EXE (Fig. 2).
Japanese patients comprised the largest subset within the
Asian subgroup, and nearly 15 % of the overall BOLERO-
2 patient population. Therefore, additional analyses spe-
cific to the Japanese subset were feasible, and indicated
that treatment with EVE ? EXE significantly improved
median PFS versus PBO ? EXE by 42 % (HR = 0.58) in
these patients. The median PFS results also favored the
combination of everolimus and exemestane in European
and North American patients (Fig. 3).
There were no complete responses (CRs) recorded for
either the EVE ? EXE or the PBO ? EXE arm. No partial
responses (PRs) were observed with PBO ? EXE in the
Asian subset, compared with 19 PRs (19.4 %) in the
EVE ? EXE arm based on local investigator assessment.
Overall, Asian patients had greater CBR and ORR in the
EVE ? EXE arm than in the PBO ? EXE arm (CBR, 58.2
vs. 28.9 %; ORR, 19.4 % vs. 0, respectively; Table 3).
For non-Asian patients, the median PFS per investigator
assessment in the 2 arms was 7.33 months and 2.83 months,
respectively (HR = 0.41; 95 % CI, 0.33–0.50; Table 3,
Fig. 2). Based on local investigator assessment, there were 3
CRs and 39 PRs (10.1 %) among non-Asian patients in the
EVE ? EXE arm versus no CRs and 4 PRs in the PBO ?
EXE arm. The CBR and ORR for non-Asian patients were
49.6 and 10.9 % in the combination arm versus 25.8 and
2.1 % in the PBO ? EXE arm, respectively (Table 3).
Safety
Across the entire study, the most common treatment-emer-
gent AEs in the EVE ? EXE arm included stomatitis and
rash; these were also the most common AEs among both
Asian and non-Asian patients (Table 4) [15]. Some AEs were
reported in a higher percentage of Asian patients compared
with the non-Asian patients. These included stomatitis, rash,
dysgeusia, pneumonitis, nail disorder, increased LDH,
nasopharyngitis, and ILD. Specifically, the rates of grade 1
and 2 dysgeusia were higher in Asian versus non-Asian
patients in the EVE ? EXE arm (30.6 vs. 19.8 %) but
comparable in the PBO ? EXE arm (6.7 vs. 5.7 %). The
incidence of nasopharyngitis was similar across treatment
arms, but much higher in Asian than non-Asian patients in
both the EVE ? EXE (22.4 vs. 7.0 %) and PBO ? EXE
(20.0 vs. 6.2 %) arms; all events were grades 1 or 2 (Table 4).
Pneumonitis, which was reported only in the EVE ? EXE
arm, was higher in Asian patients than in non-Asian patients
in the EVE ? EXE arm (23.5 vs. 14.1 %, respectively).
However, the frequency of grade 3 and 4 pneumonitis was
Table 2 Duration of exposure to study treatment
Asian patients Non-Asian patients
Everolimus ? exemestane
(n = 98)
Placebo ? exemestane
(n = 45)
Everolimus ? exemestane
(n = 384)
Placebo ? exemestane
(n = 193)
Everolimus Exemestane Placebo Exemestane Everolimus Exemestane Placebo Exemestane
Duration (weeks)
Median 27.6 32.6 18.0 18.0 23.7 28.1 13.1 13.9
Range 2.0–123.3 2.0–123.3 2.0–101.0 4.0–101.0 1.0–109.4 1.0–109.4 1.0–82.0 1.0–82.0
708 Breast Cancer (2014) 21:703–714
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lower in Asian patients compared with non-Asian patients
(2.0 vs. 3.6 %, respectively). In contrast, hot flushes were
comparable in incidence between Asian and non-Asian
patients. They were, however, less frequent in Asian and non-
Asian patients in the EVE ? EXE arm (6.1 and 5.5 %) than
in the PBO ? EXE arm (13.3 and 14.5 %) (Table 4).
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Notably, the incidence of grade 3 and 4 AEs among
patients who received EVE ? EXE was generally similar
or lower in Asian patients compared with non-Asian
patients (Table 4). The only exceptions were increased
aspartate aminotransferase (AST) levels and cough. The
most common grade 3 and 4 AEs (C5 %) for both Asian
and non-Asian patients in the EVE ? EXE treatment group
included stomatitis (8.2 vs. 7.8 %), anemia (7.1 vs. 7.6 %),
increased AST levels (6.1 vs. 2.9 %), hyperglycemia (4.1
vs. 6.0 %), and dyspnea (3.1 vs. 5.7 %), respectively.
There were very few grade 4 AEs reported, regardless of
treatment arm or ethnicity subset, and none were reported
in at least 5 % of the patients studied (Table 4).
Quality of life in Asian patients
Treatment with EVE ? EXE did not affect TTD in
EORTC QLQ-C30 GHS compared with PBO ? EXE in
Asian patients. At the protocol-defined threshold of 5 %
decrease from baseline, the median TTD was 8.4 months
(95 % CI, 6.9–11.1 months) in the EVE ? EXE arm com-
pared with 5.6 months (95 % CI, 2.9–15.2 months) in the
PBO ? EXE arm (HR = 0.79; 97.5 % CI, 0.44–1.44; Fig. 4).
Discussion
Although women with HR? breast cancer often respond to
multiple lines of endocrine therapy, most ultimately pro-
gress. When patients with HR? advanced breast cancer
progress despite nonsteroidal aromatase inhibitors, the
current treatment paradigm includes EXE followed by
tamoxifen, toremifene, or fulvestrant [4]. This paradigm is
followed in Asia as well as in Western countries. Once
patients progress on initial endocrine therapy, the available
treatment options offer limited clinical benefit and poor
survival [5]. New treatment options are needed that can
offer patients with advanced breast cancer the hope of
overcoming resistance, prolong the time for which endo-
crine therapy is effective, and delay chemotherapy.
In the phase 3 BOLERO-2 study, the addition of EVE to
EXE increased median PFS by 4.6 months [12]. These
results suggest that inhibition of cross-talk pathways
(PI3K/mTOR) may help improve outcomes in this patient
population. Nearly 20 % of the 724 patients in this study
were Asian, providing an opportunity to determine the
efficacy and safety of EVE in this important subgroup.
Ethnic differences can account for variations in both the
pharmacokinetics and pharmacodynamics of anticancer
agents, potentially resulting in alterations of the safety and
efficacy profiles of these agents [13]. For example, doce-
taxel, like gefitinib [15], has demonstrated enhanced effi-
cacy in Asian versus Caucasian patients [13]. This was
accompanied, however, by higher incidence of febrile
neutropenia requiring hospitalization [13]. CYP2D6
genetic polymorphisms have been shown to affect the
conversion of tamoxifen to its most active metabolite,
endoxifen. As a result, the efficacy of tamoxifen might vary
according to the distribution of these genetic polymor-
phisms among various ethnic populations [13]. The distri-
bution of genetic polymorphisms affecting CYP2D6
activity is different between Asian and non-Asian patients.
Thus, it is hypothesized that the efficacy of tamoxifen may
also be different between these patient populations [13]. To
ensure optimal treatment response and understand the
safety profile, it is important to consider the potential inter-
ethnic differences in anticancer drug effects [13].
We have demonstrated in this report that the efficacy of
EVE is consistent between the Asian and non-Asian sub-
groups. Combining EVE with EXE more than doubled the
median PFS versus EXE with PBO, from 4.14 to
8.48 months for Asians and from 2.83 to 7.33 months for
Table 3 Best response
Asian Non-Asian
Everolimus ? exemestane
(n = 98)
Placebo ? exemestane
(n = 45)
Everolimus ? exemestane
(n = 387)
Placebo ? exemestane
(n = 194)
Best overall response, %
Complete 0 0 \1 0
Partial 19 0 10 2
Stable disease 66 78 73 55
Progressive disease 11 20 10 36
Unknown 3 2 7 8
Objective response rate, %a 19 0 11 2
Clinical benefit rate, %b 58 29 50 26
a Complete and partial responses
b Complete and partial responses plus stable disease C24 weeks
710 Breast Cancer (2014) 21:703–714
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Table 4 Treatment-emergent adverse events with at least 10 % incidence in the everolimus ? exemestane arm in the Asian and non-Asian
subpopulations
Adverse Event, %
Asian Patients Non-Asian Patients
Everolimus Plus 
Exemestane 
(n = 98)
Placebo Plus 
Exemestane
(n = 45)
Everolimus Plus 
Exemestane 
(n = 384)
Placebo Plus 
Exemestane
(n = 193)
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Stomatitis 43 29 8 0 13 2 0 0 25 21 8 0 8 2 1 0
Rash 38 12 0 0 7 2 0 0 26 9 2 0 4 2 0 0
Fatigue 15 6 3 0 13 4 0 0 19 16 4 <1 17 11 2 0
Diarrhea 21 2 0 0 11 2 0 0 27 7 3 <1 15 4 1 0
Decreased appetite 10 8 1 0 4 2 2 0 22 10 2 0 9 5 <1 0
Nausea 18 4 0 0 22 2 0 0 22 10 <1 <1 20 8 2 0
Cough 17 0 3 0 2 4 0 0 22 5 <1 0 10 3 0 0
Dysgeusia 26 5 0 0 7 0 0 0 16 4 0 0 6 0 0 0
Headache 24 1 0 0 11 0 0 0 15 7 <1 0 13 3 0 0
Decreased weight 7 15 1 0 0 7 0 0 10 17 2 0 3 4 0 0
Dyspnea 5 0 3 0 0 0 0 0 12 8 6 <1 10 2 1 <1
Arthralgia 14 2 0 0 9 0 0 0 15 6 1 0 11 7 <1 0
Anemia 1 6 6 1 0 0 2 0 4 10 7 <1 3 3 0 1
Epistaxis 15 0 0 0 2 0 0 0 16 2 0 0 1 0 0 0
Vomiting 9 4 0 0 9 0 0 0 11 6 1 <1 9 4 1 0
Peripheral edema 6 2 0 0 4 0 0 0 16 7 1 0 5 1 <1 0
Pyrexia 15 1 0 0 9 0 0 0 12 3 <1 0 5 1 <1 0
Hyperglycemia 2 3 4 0 0 2 2 0 4 6 6 <1 1 <1 0 0
AST increased 7 5 6 0 2 0 0 0 5 5 3 <1 2 3 2 0
Constipation 17 2 1 0 9 0 2 0 10 3 <1 0 8 6 0 0
Pneumonitis 13 8 2 0 0 0 0 0 6 5 4 0 0 0 0 0
Thrombocytopenia 8 4 3 0 0 0 0 0 6 4 2 1 0 0 0 <1
Asthenia 0 1 0 0 0 0 0 0 8 7 2 0 4 1 <1 0
ALT increased 10 4 3 0 0 0 2 0 4 4 3 <1 1 2 2 0
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non-Asians. Asian patients also experienced a greater CBR
and ORR after receiving EVE ? EXE versus PBO ? EXE.
Median exposure to EVE ? EXE was nearly 4 weeks
longer in Asian versus non-Asian patients. Despite the
longer exposure to EVE ? EXE in Asian patients, the
frequency of drug discontinuation for these patients was
lower than for non-Asian patients. Also, there were no
significant differences in TTD of EORTC QLQ-C30 GHS
for the Asian subset of patients. Finally, treatment-emer-
gent AEs were comparable across the two groups.
Some AEs (e.g., stomatitis, nasopharyngitis, pneumo-
nitis, and ILD) were slightly more frequently reported
among Asian patients. Others (e.g., anemia) were less
frequent. However, all AEs were generally consistent with
those reported for EVE in the overall BOLERO-2 study
[16]. Similar AEs were seen in other indications following
EVE treatment [23]. Occurrences of grade 3 and 4 anemia,
stomatitis, abnormal liver enzymes, fatigue, and hyper-
glycemia have also been frequently reported in Japanese
patients with metastatic gastric cancer treated with EVE
monotherapy following progression on chemotherapy [24].
Effective management of AEs associated with the use of
EVE requires patient education, physician awareness, and
early intervention [16]. In some cases (e.g., more severe
instances or higher grades of these AEs), dose modifica-
tions and standard care have proven useful [12, 25].
Interstitial lung disease (ILD; characterized by the
inflammation of the interstitium of the lung) and non-
infectious pneumonitis (characterized by the presence of
non-infectious, nonmalignant infiltrates) are known side
effects of mTOR inhibitors [26, 27]. In the current study,
AEs including ILD and non-infectious pneumonitis were
coded using the MedDRA terminology (version 14.0) and
were assessed as described in the ‘‘Methods’’ section. An
Table 4 continued
Pruritus 10 2 0 0 4 2 0 0 11 3 <1 0 3 2 0 0
Insomnia 10 2 1 0 4 0 0 0 10 4 0 0 6 3 0 0
Back pain 9 2 0 0 4 0 0 0 10 6 <1 0 6 4 2 0
Dry mouth 3 0 0 0 2 0 0 0 12 2 0 0 8 <1 0 0
Alopecia 5 0 0 0 2 0 0 0 10 1 0 0 6 0 0 0
Pain in extremity 4 1 0 0 0 4 0 0 7 3 <1 0 6 5 2 0
GGT increased 1 2 4 0 0 0 2 0 2 2 5 2 1 1 5 3
Hypercholesterolemia 4 4 0 0 0 0 0 0 7 3 <1 <1 1 0 0 0
Nasopharyngitis 21 1 0 0 20 0 0 0 6 1 0 0 4 3 0 0
Nail disorder 21 1 0 0 0 0 0 0 4 <1 0 0 <1 0 0 0
Hot flush 6 0 0 0 13 0 0 0 5 <1 0 0 10 5 0 0
LDH increased 12 1 1 0 2 0 0 0 2 2 0 0 0 2 0 0
ILD 8 4 1 0 0 0 0 0 0 <1 <1 0 0 0 0 0
Adverse Event, %
Asian Patients Non-Asian Patients
Everolimus Plus 
Exemestane 
(n = 98)
Placebo Plus 
Exemestane
(n = 45)
Everolimus Plus 
Exemestane 
(n = 384)
Placebo Plus 
Exemestane
(n = 193)
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
Gr 
1
Gr 
2
Gr 
3
Gr 
4
ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, ILD interstitial lung disease, LDH lactate
dehydrogenase
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increased frequency of ILD has been reported in Japanese
cancer patients receiving molecular targeted anticancer
therapies such as gefitinib and erlotinib [15]. The patterns of
ILD were also the focus of a recent study that retrospec-
tively evaluated 7 Japanese patients treated with EVE for
advanced renal cell carcinoma [28]. Patients with mild ILD
were able to continue EVE treatment. More severe ILD led
to EVE discontinuation and short-term steroid therapy,
which generally resulted in rapid resolution of ILD. Prompt
recognition of ILD incidence or exacerbation, and exclusion
of progressive disease or infection, were determined to be of
paramount importance for the successful management of
these AEs [28]. The frequency of ILD overall was higher in
the Asian patients in this BOLERO-2 study; nonetheless,
grade 3 and 4 ILD occurred with similar low frequencies in
Asian and non-Asian patients. Whereas pneumonitis, like
ILD, was more prevalent in Asian patients treated with
EVE ? EXE, some of the symptoms of pneumonitis, such
as dyspnea and cough, were less frequent in the Asian
patients in the EVE ? EXE arm. This demonstrates that
EVE treatment is not associated with any exacerbated safety
concerns based on patient ethnicity.
In conclusion, combining EVE with EXE provided sub-
stantial clinical benefit to both Asian and non-Asian patients.
EVE was well tolerated and most of the EVE-related AEs
were manageable. Observed AEs in BOLERO-2 were con-
sistent with AEs previously reported for rapamycin analogues
[29, 30]. This combination of EVE ? EXE did not affect self-
assessed QOL in Asian patients. Thus, EVE ? EXE repre-
sents an important improvement in the management of post-
menopausal women with HR? HER2- advanced breast
cancer progressing after nonsteroidal aromatase inhibitor
treatment, regardless of ethnicity.
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